Drug Trial Radar · NCT05009992
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Oct 20, 2021
Primary completion
Dec 31, 2027
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Chad-Tough Defeat DIPG Foundation; Mithil Prasad Foundation; Storm the Heavens Fund; National Institute of Neurological Disorders and Stroke (NINDS); Jazz Pharmaceuticals; Neeve Kolte and Brave Ronil Foundation; Will Meeker Foundation; CV Biomanufacturing; Tough2gether Foundation
- First posted
- Aug 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. This trial will utilize an adaptive platform design in that the different treatment arms for each cohort will be opened and closed based on ongoing preclinical investigation as well as evolving outcome data from the trial. Novel agents will be continuously added to this study as pre-clinical data emerge to suggest additive or synergistic activity when combined ONC201. Should a novel agent not have an RP2D at the time of incorporation into this study, a phase 1 lead-in will be performed prior to initiation of combination therapy (via study amendment).
Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Recurrent Diffuse Intrinsic Pontine Glioma
- Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
- Recurrent WHO Grade III Glioma
- WHO Grade III Glioma
Interventions
ONC201Drug
Given orally (PO)
Radiation TherapyRadiation
Undergo radiation therapy
PaxalisibDrug
Given PO
DNX-2401Drug
DNX-2401 is an oncolytic adenovirus that will be administered through direct intratumoral infusion of DNX-2401 via a specialized Neuro Ventricular Cannula.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B OnlyTime frame: 6 months after diagnosis
- Progression-free survival at 6 months (PFS6) - Cohorts 2A, 2B OnlyTime frame: 6 months after diagnosis
- Overall survival at 7 months (OS7) - Cohort 3A & 3B OnlyTime frame: 7 months after administration of ONC201 in the maintenance phase
- Proportion of participants reporting dose-limiting toxicities (DLTs) (Cohort 4)Time frame: Up through the first cycle of maintenance therapy, approximately 8 months
- Number of participants requiring dose modification through first cycle of maintenance (Cohort 5)Time frame: Up through the first cycle of maintenance therapy, approximately 8 months
- Maximum tolerated number of intratumor infusions of DNX-2401, with a maximum of 6, in participants with thalamic or pontine DMG who have completed radiotherapy (Cohort 6)Time frame: A maximum of 6 infusions will be administered every 30 days - approximately 8 months
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
University of California, San Diego / Rady Children's Hospital, San Diego
San Diego, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Indiana University Riley Children's Hospital
Indianapolis, Indiana · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute Harvard University
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Children's Hospital Minnesota
Minneapolis, Minnesota · Recruiting
Washington University in St. Louis
St Louis, Missouri · Recruiting
Hackensack Meridian Health
Hackensack, New Jersey · Recruiting
New York University
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Women and Children's Hospital
Adelaide, Australia · Recruiting
Sydney Children's Hospital
Sydney, Australia · Active not recruiting
John Hunter Children's Hospital
New Lambton Heights, New South Wales, Australia · Recruiting
The Children's Hospital at Westmead
Westmead, New South Wales, Australia · Active not recruiting
Queensland Children's Hospital
South Brisbane, Queensland, Australia · Active not recruiting
Monash Children's Hospital
Clayton, Victoria, Australia · Recruiting
The Royal Children's Hospital Melbourne
Melbourne, Victoria, Australia · Active not recruiting
Perth Children's Hospital
Nedlands, Washington, Australia · Recruiting
Shaare Zedek Medical Center
Jerusalem, Israel · Recruiting
Sheba Medical Center
Tel HaShomer, Ramat Gan, Israel · Recruiting
Princess Maxima Center
Utrecht, Netherlands · Active not recruiting
Starship Children's Hospital
Auckland, New Zealand · Recruiting
The University Children's Hospital in Zurich
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.